Ambusol AB (publ)
Pioneering patented therapy to eradicate residual glioblastoma cells post-surgery.
Overview
- 1–4
- Employees
- 100–149K SEK
- Revenue
- 2023
- Founded
Key Decision Makers
Göran Ronquist
Founder and board member (Chemist and Researcher)
Owe Orwar
Senior Adviser to the board
Frederic Telander
Founder and chairman of the board (Corporate Leader)
Holger Ronquist
Founder and board member (International businessman)
+2 more contacts in Funnelfeedr
Description
Ambusol is a clinical-stage cancer therapeutics company focused on revolutionizing the treatment of glioblastoma (GBM). Their core mission is to eradicate residual GBM cells remaining in the surgical margins after operation, offering new hope to patients. The company pioneers a patented approach uti...
Tags
Keywords
Company Information
- Industry
- Tillverkning av läkemedel
- Legal Form
- Aktiebolag
- VAT Number
- SE559465830301
Decision Makers
6 contacts in FunnelfeedrGöran Ronquist
Founder and board member (Chemist and Researcher)
Owe Orwar
Senior Adviser to the board
Frederic Telander
Founder and chairman of the board (Corporate Leader)
Holger Ronquist
Founder and board member (International businessman)
Maximilian Telander
CEO, founder and board member
Gunnar Ronquist
Founder and board member (Physician and Researcher)
Similar Companies
20 similar companies in Funnelfeedr
Isofol Medical AB (publ)
10–19 employeesDeveloping next-generation folate drug to improve cancer treatment efficacy.
AcroPharma AB (publ)
0 employeesDeveloping innovative preventive therapeutics for major human diseases.
Mendus AB (publ)
Developing immune-based cancer therapies to prevent recurrence.
Akiram Therapeutics AB
Pioneering targeted radioimmunotherapy to treat incurable solid tumors effectively.
AAX Biotech AB
5–9 employeesResearch-driven biotech advancing antibody therapies via proprietary technology.
Browse More
Ambusol AB (publ) Questions
Want to see Funnelfeedr in action?
Book a free demo and discover how Funnelfeedr helps you find and convert your ideal customers.
Book a demo